SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SAN DIEGO, April 11, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that TRC105 prostate cancer-related clinical data will be presented at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 16-20, 2016, in New Orleans, LA.
Dr. Liang Cao and colleagues at the National Cancer Institute will present a poster featuring data from a previous clinical study of TRC105 in prostate cancer. The presentation details are as follows:
| Abstract Number: | 2048 | ||||
| Abstract Title: | Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion | ||||
| Presenter: | Liang Cao, Ph.D., National Cancer Institute, Bethesda, MD | ||||
| Location: | Section 14, Poster Board Number 20 | ||||
| Date: | Monday, April 18, 2016 | ||||
| Time: | 1:00pm – 5:00pm CDT | ||||
The poster will be available on the Company’s website.
About TRC105
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
